Mirikizumab Offers Durable Response Up to 2 Years in UC Mirikizumab Offers Durable Response Up to 2 Years in UC
A long-term maintenance study suggested continuing mirikizumab for 104 weeks is safe and provides durable benefit in patients with active ulcerative colitis.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Gastroenterology Source Type: news
More News: Drugs & Pharmacology | Gastroenterology | Inflammatory Bowel Disease | Study | Ulcerative Colitis